Dublin, May 24, 2018 (GLOBE NEWSWIRE) -- The "Intranasal Drug Delivery - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for this market. Market data and analytics are derived from primary and secondary research. This report analyzes the US Market for Intranasal Drug Delivery in US$ Million by the following Therapeutic Areas:
- Allergic Infections
- Analgesics
- Osteoporosis
- Vaccinations
The report profiles 64 companies including many key and niche players such as:
- Aegis Therapeutics LLC (USA)
- AptarGroup, Inc. (USA)
- AstraZeneca Plc. (UK)
- MedImmune, Inc. (USA)
- Becton Dickinson and Company (USA)
- GlaxoSmithKline Plc. (UK)
- Johnson & Johnson Inc. (USA)
- Marina Biotech, Inc. (USA)
- Merck & Co., Inc. (USA)
- Nemera (France)
- Novartis AG (Switzerland)
- OptiNose US Inc. (USA)
- Pfizer, Inc. (USA)
- Valeant Pharmaceuticals International, Inc. (Canada)
Key Topics Covered:
1. INDUSTRY OVERVIEW A Prelude Intranasal Cavity: An Attractive Drug Delivery Route to Cross the Blood Brain Barrier Factors Inhibiting Nose-to-Brain Transportation of Drugs Drug's Physico-Chemical Properties Drug Dose, Concentration & Volume Administration Mucociliary Clearance Existence of Enzymatic Activity Animal Species: Variations in Nasal Mucosa Overcoming Barriers to Nose-to-Brain Delivery of Drugs Prodrug Technique Innovative Formulation Use of Enzyme Inhibitors & Absorption Enhancers Bioavailability: An Important Facet of Intranasal Drug Delivery Chemical Modification Transient Modification & Limited Enzymatic Activity Bioavailability of Large Molecules Bio-Adhesive Polymers: Useful in Increasing Drug Absorption Outlook Nasal Drug Delivery Devices & Equipment Preservative Free Systems (PFS) Traditional Vs. Advanced Intranasal Drug Formulation Types Type of Nasal Delivery Vehicles with Select Therapeutic Agents and Area of Application 2. MARKET DRIVERS, TRENDS & ISSUES Burgeoning Geriatric Populace Spurs Growing Demand for Intranasal Drug Therapies Nasal Drug Delivery Offers New Opportunities for Drug Developers as Patent Cliffs Usher in Dusk of Blockbuster Era Pharmaceutical and Medical Device Companies Vying to Develop New Intranasal Therapeutics for Allergic Rhinitis Patients The US FDA Approved Intranasal Corticosteroids (INAC) and Intranasal Antihistamines (INAH) for Treating Allergic Rhinitis FDA Approved Nasal Spray Medication Types (excluding INAC & INAH) for Allergic Rhinitis Treatment Intranasal Corticosteroids A Potential Treatment for Debilitating Chronic Rhinosinusitis Disease Select Intranasal Corticosteroid Brands for Adult and Pediatric Usage Self-Administration of Drugs Brings Intranasal Drug Delivery into the Spotlight Innovation in Drug Delivery: A Talisman for Success Active Pharmaceutical Ingredients Used in Formulations for Nasal Drug Delivery with Related Indications Controlled Release Technology Is the Buzz Word Target-Specific Delivery Devices: Of Critical Value Safety and Cost: Primary Growth Drivers Increasing R&D Unlocks New Therapeutic Areas for Nasal Drug Delivery Intranasal Therapeutics Delivery A High Potential Method for Treating CNS Diseases Intranasal Insulin Delivery Offers Strong Clinical Significance Inhaled Insulin Market Challenged by Low Acceptance Levels Intranasal Delivery of Anti-emetic Agent Metoclopramide Hydrochloride Validated by Study on Rodents Intranasal Delivery of Peptide-Based Pharmaceuticals Select Protein, Peptide & Non-Peptide Drugs Available as Nasal Spray Solutions in the Marketplace Tight Junction Biology: A Key Speed Breaker in Commercialization RNA Interference (RNAi): A Tool to Manipulate Tight Junctions Research Studies Authenticate Benefits of Bi-Directional Nasal Drug Delivery Growing Interest for Preservative-free Nasal Spray Formulations Multi-Dose Containers Developed to Offer Resistance against Microbial Contamination 3. RECENT RESEARCH & DEVELOPMENT INITIATIVES OptiNose XHANCE Nose-to-Brain Drug Delivery OPN-300 A Potential Alternative for Many Brain Disorders Orexin-A Replacement for Treating Nacrolepsy Advanced Nanoparticle Nasal Spray to Enable Drug Delivery to Brain OptiNose Develops Innovative Treatment Option for Sinusitis Intranasal Administration of ATX-LIPO for Brain Targeting A Promising Therapy for ADHD Noteworthy Registered and Published Clinical Trials on Intranasal Psychotropics Focused Ultrasound Leveraged to Enhance Intranasal Drug Delivery Evoke Pharma Develops EVK-001 Intranasal Metoclopramide Delivery System for Treating Gastroparesis Smart Polymers with Temperature, pH or Ionic Response in Nasal drug Delivery Chitosan Thermosensitive Biogels Evaluated for Intranasal Delivery of CNS Drugs Select Nasal Drug Absorption Enhancers and Related Mechanisms Dendrimers to Enhance Water-solubility of Antipsychotic Drugs for Intranasal Administration Naloxone Hydrochloride Nasal Sprays Provides a Powerful Alternative for Opioid Overdose Medications OptiNose ONZETRA Xsail (AVP-825) An Innovative Breath- Powered Intranasal Delivery System for Migraine Treatment Clinical Study Demonstrates Faster Antidepression Effects of Intranasal Ketamine Intranasal Aerosol Dose of PH94B Investigated for Treating Social Anxiety Disorder (SAD) 4. TECHNOLOGY OVERVIEW Intranasal Drug Delivery: A Descriptive Exposition Nasal Physiology Challenges Involved In Formulating Nasal Drugs The Importance of Bioadhesion Overview of the Traditional Drug Administration Routes, Molecular Weight Capabilities, and Dosage Range Intranasal Drugs Prescription (Rx) and Over-the-Counter (OTC) Differences between Systemic Delivery and Local Effects Nasal Powders Vs. Sprays Nasal Drug Delivery Devices Types of Drug Delivery Devices Droppers Sprays Aerosol Containers/Inhalers Pumps Nasal Aspirators Intranasal Drug Delivery Vis--vis Other Delivery Techniques Limitations of Intranasal Drug Delivery Allergy Definition Symptoms Allergic Rhinitis Nasal Allergies 5. NASAL DELIVERED DRUGS: AN OVERVIEW Nasal Drugs for Allergies Corticosteroid Nasal Sprays Flonase Patanase Beconase Other Nasal Corticosteroid Drugs Antihistamine Nasal Sprays Astelin Nasal Spray Otrivin Nasal Spray Livostin Nasal Spray Other Nasal Antihistamine Drugs Select Brands of Allergy Relievers Nasal Drugs for Postmenopausal Osteoporosis Calcitonin-Salmon Nasal Spray Miacalcin Nasal Spray Fortical Nasal Spray Intranasal Pain Management Drugs Stadol Nasal Spray Imitrex Migranal Zolmitriptan Nasal Spray Intranasal Analgesics for Treating Migraine Intranasal Vaccination Process of Intranasal Immunization "LAIV" Nasal Spray Flu Vaccine FluMist Vaccine from MedImmune Intranasal Drugs for Sexual Dysfunction Nasal Spray for Treating Vitamin B12 Deficiency Nasal Spray for Aiding Smoking Cessation 6. PRODUCT DEVELOPMENTS, APPROVALS & INTRODUCTIONS FDA Approves OptiNose XHANCE Nasal Spray Splintek Launches Intra-Nasal Sleep Inhaler Allergan Receives Market Authorization for TrueTear St. Renatus Launches Kovanaze Nasal Spray Perrigo and West-Ward Pharmaceuticals Launch Generic Store Brand Flonase Nemera Launches Advancia Multi-Dose Nasal Spray System Adapt Pharma Launches Narcan Opioid Antagonist Apotex Unveils Generic Version of Nasonex McNeil Consumer Healthcare Rolls Out OTC RHINOCORT OptiNose Bags FDA Approval for ONZETRA Xsail Avanir's Onzetra Secures FDA Approval FDA Approves Lannett's Sumatriptan Nasal Spray Meda's Dymista Bags Health Canada's Approval Endo Pharmaceuticals Announces Availability of NATESTO AstraZenca Canada Unveils FluMist for Children Perrigo Receives US FDA Approval for Generic Version of Sun Pharma's Kenalog GSK Rolls Out OTC Version of Flonase Allergy Relief Upsher-Smith Publishes Data from USL261 Phase 1 Trials KemPharm Concludes KP201/APAP's Human Abuse Liability Program OptiNose Publishes Results of OPN 375's Phase III Trial NanoBio's Genital Herpes Vaccine Proven Effective Recro Pharma Releases Further Details of Dex-IN's Phase II Clinical Trial Evoke Announces Phase III Trials of EVK-001 FDA Accepts Filing of TARSA's TBRIA FDA Accepts Review of Pfizer's ALO-02 Breckenridge Bags FDA Approval for Azelastine HCl Nasal Solution ZOMIG Gets FDA Approval 7. RECENT INDUSTRY ACTIVITY Opiant Pharmaceuticals to Pursue Development of Intranasal Nalmefene Egalet and OraPharma to Co-Promote SPRIX Nasal Spray Aegis Develops Hydromorphone Nasal Spray Emergent Biosolutions to Develop Intranasal Spray for Treatment of Cyanide Poisoning Aptar Pharma to Manufacture Child-Resistant Nasal Pumps in North America Therapix and Yissum Sign License for Cannabinoid Nasal Drug Delivery Technology Impel NeuroPharma and Camargo Pharmaceutical Services Sign Service Agreements Egalet Inks Deal With Septodont for SPRIX Promotion Lilly Acquires Intranasal Glucagon Rights UAE recalls Otrivin Nasal Spray Batches Eli Lily Acquires Rights for Innovent's Intranasal Glucagon AstraZenca Commences Shipment of FluMist 8. FOCUS ON SELECT PLAYERS 9. US MARKET ANALYTICS
Total Companies Profiled: 64 (including Divisions/Subsidiaries 81)
- The United States (48)
- Canada (4)
- Japan (2)
- Europe (17)
- France (2)
- Germany (4)
- The United Kingdom (4)
- Rest of Europe (7)
- Asia-Pacific (Excluding Japan) (7)
- Middle East (2)
- Latin America (1)
For more information about this report visit https://www.researchandmarkets.com/research/p..._drug?w=12
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Transdermal and Transmucosal Drug Delivery
